Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICHE trial in early-stage colon cancer
2024-513314-35-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, relatlimab, anti-IL-8 monoclonal antibody and celecoxib in colon adenocarcinoma and Rectosigmoid Adenocarcinoma (4 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Major pathologic response rate. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
colon adenocarcinomaRectosigmoid Adenocarcinoma
Beyond the preview
Go deeper on 2024-513314-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513314-35-00.